Dothan – Enrolling Now

  1. Boreas, “A randomized, double-blind, placebo-controlled, parallel-group, 52-week pivotal study to assess the efficacy, safety, and tolerability of Dupilumab in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) with Type 2 inflammation.”

    We need volunteers who have experienced at least two flare-ups (exacerbations) of COPD within the past 12 months in spite of taking long acting respiratory inhalers. This study is evaluating an injection therapy as a possible means of reducing the frequency of COPD exacerbations.